SEARCH

SEARCH BY CITATION

References

  • 1
    Warner M. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. Centers for Disease Control and Prevention, no. 22, September, 2009. Available from http:www.cdc.govnchsdatadatabriefsdb22.htm. Accessed March 15, 2010.
  • 2
    Drug Abuse Warning Network. Dawn report: emergency department visits involving nonmedical use of selected pharmaceuticals. Available from http:dawninfo.samhsa.govfilestndr2006-07rtndr07edvisitsnonmedicaluse.htm. Accessed October, 2009.
  • 3
    Szabo L. Prescriptions now biggest cause of fatal drug overdoses. USA Today. October 1, 2009: D1.
  • 4
    Potter M. Prescription drug abuse ravages state's youth. MSNBC.com. Available from http:www.msnbc.msn.comid31707246nshealth-addictionsprint1displaymode1098. Accessed July 6, 2009.
  • 5
    Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the U.S. Pharmacoepidemiol Drug Saf 2006;15: 61827.
  • 6
    Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300: 261320.
  • 7
    Havens JR, Walker R., Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug and Alcohol Dependence 2007;87: 98102.
  • 8
    Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31: 50611.
  • 9
    Wunsch MJ, Nakamoto K., Behonick G., Massello W. Opioid deaths in rural Virginia: description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009;18: 514.
  • 10
    International Medication Systems, Ltd. Naloxone hydro-choride injection package insert. South El Monte, CA; April 2006.
  • 11
    McEvoy GK, ed. Naloxone hydrochloride. In: AHFS drug information 2009. Bethesda, MD: American Society of Health-System Pharmacists, 2009: 22514.
  • 12
    Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 10th ed. New York: McGraw-Hill, 2001: 569620.
  • 13
    Sporer KA, Kral AH. Out of hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med 1996;3: 6607.
  • 14
    Belz D., Lieb J., Rea T., Eisenberg MS. Naloxone use in a tiered response emergency medical services system. Prehosp Emerg Care 2006;10: 46871.
  • 15
    Kerr D., Dietze P., Kelly A. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction 2008;103: 37986.
  • 16
    Wanger K., Brough L., Macmillan I., Goulding J., MacPhail I., Christenson JM. Intravenous versus subcutaneous naloxone for out of hospital management of presumed opioid overdose. Acad Emerg Med 1998;5: 2939.
  • 17
    Doe-Simpkins M., Walley A., Epstein A., et al. Saved by the nose: bystander administered intranasal naloxone hydro-chloride for opioid abuse. Am J Public Health 2009;99: 78891.
  • 18
    Kim D., Irwin KS, Khoshknod K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose and mortality. Am J Public Health 2009;99: 4027.
  • 19
    Barton ED, Ramos J., Colwell C., Benson J., Baily J., Dunn W. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care 2002;6: 548.
  • 20
    Barton ED, Colwell CB, Wolfe T., et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the pre-hospital setting. J Emerg Med 2005;29: 26571.
  • 21
    Kelly AM, Kerr D., Dietze P., Patrick I., Walker T., Koutsogiannis Z. Randomized trial of intranasal versus intramuscular naloxone in prehospital treatment of suspected opioid overdose. Med J Aust 2005;182: 247.
  • 22
    Robertson GW, Stroh G., Shalit M. Intranasal vs intravenous naloxone for prehospital narcotic overdose [abstract]. Acad Emerg Med 2005;12(5 suppl 1): 166.
  • 23
    Robertson TM, Hendey GW, Stroh G., Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehospital Emerg Care 2009;13: 51215.
  • 24
    Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 2001;100: 182331.
  • 25
    Seal KH, Thawley R., Gee L., et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 2005;82: 30311.
  • 26
    Maxwell S., Bigg D., Stanczykiewicz K., Carlberg S. Prescribing naloxone to actively injection heroin users: a program to reduce heroin overdose death. J Addictive Dis 2006;25: 8996.
  • 27
    Piper TM, Rudenstine S., Stancliff S., et al. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduction J 2007;4: 18.
  • 28
    Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 2007;49: 1727.
  • 29
    Green TC, Heimer R., Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and distribution programs in the US. Addiction 2008;103: 97989.
  • 30
    Strang J., Manning V., Mayet S., et al. Family carers and the prevention of heroin overdose deaths: unmet training need and overlooked intervention opportunity of resuscitation training and supply of naloxone. Drug Education, Prevention and Policy 2008;15: 21118.
  • 31
    Sherman SG, Gann DS, Tobin KE, et al. The life they save may be mine”: diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy 2009;20: 13742.